Search Result

Results for "

JAK1/TYK2-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Isotope-Labeled Compounds (1) JAK (21) Reference Standards (1) STAT (1) Syk (1)
By Research Areas:	Cancer (8) Inflammation/Immunology (13)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Dan family AIM2 NEKs CD44

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100895

SAR-20347 1 Publications Verification	JAK	Cancer
SAR-20347 is an inhibitor of *TYK2, JAK1*, JAK2 and JAK3 with IC₅₀s of 0.6, 23, 26 and 41 nM, respectively.

HY-109053

Delgocitinib 2 Publications Verification JTE-052	JAK	Inflammation/Immunology
Delgocitinib (JTE-052) is a specific JAK inhibitor with IC₅₀s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-19568

Peficitinib Maximum Cited Publications 8 Publications Verification ASP015K; JNJ-54781532	JAK	Inflammation/Immunology
Peficitinib (ASP015K) is an orally active JAK inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-120469

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK	Inflammation/Immunology
GDC-046 is a potent, selective, and orally bioavailable *TYK2* inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively .

HY-145336

*JAK1/TYK2-IN-1*	JAK	Cancer
JAK1/TYK2-IN-1 is a dual inhibitor of *TYK2* and *JAK1* (IC₅₀ = 29 and 41 nM respectively).

HY-143885

JAK1/TYK2-IN-3	JAK	Inflammation/Immunology
JAK1/TYK2-IN-3 is a potent, selective and orally active dual *TYK2/JAK1* inhibitor with IC₅₀ values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to JAK2 (IC₅₀=140 nM) and JAK3 (IC₅₀=362 nM). JAK1/TYK2-IN-3 shows anti-inflammatory effect by regulating the expression of related *TYK2/JAK1*-regulated genes, as well as the formation of Th1, Th2, and Th17 cells .

HY-149296

JAK1-IN-12	JAK	Inflammation/Immunology
JAK1-IN-12 is a selective inhibitor of *JAK1, with IC₅₀* of 0.0246 μM. And IC₅₀s of 0.423 μM, 0.410 μM and 1.12 μM for JAK2, JAK3 and TYK2. JAK1-IN-12 promotes hair growth in mice. JAK1-IN-12 can be used for research of immune and inflammatory diseases .

HY-109053A

Delgocitinib ethanolate JTE-052 ethanolate	JAK	Inflammation/Immunology
Delgocitinib ethanolate is a specific JAK inhibitor with IC₅₀s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-19568B

Peficitinib hydrochloride ASP015K hydrochloride; JNJ-54781532 hydrochloride	JAK	Inflammation/Immunology
Peficitinib (ASP015K) hydrochloride is an orally active JAK inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-19568A

Peficitinib hydrobromide ASP015K hydrobromide; JNJ-54781532 hydrobromide	JAK	Inflammation/Immunology
Peficitinib (ASP015K) hydrobromide is an orally active JAK inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-156535

JAK kinase-IN-1	JAK	Inflammation/Immunology
JAK kinase-IN-1 (Example 1) is a JAK inhibitor. JAK kinase-IN-1 inhibits TYK2, JAK1, JAK2 and JAK3 with IC₅₀ values of 4.2 nM, 32 nM, 27 nM, 3473 nM respectively .

HY-148060

JAK-IN-21	JAK	Cancer
JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC₅₀s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively .

HY-19568R

Peficitinib (Standard) ASP015K (Standard); JNJ-54781532 (Standard)	Reference Standards JAK	Inflammation/Immunology
Peficitinib (Standard) is the analytical standard of Peficitinib. This product is intended for research and analytical applications. Peficitinib (ASP015K) is an orally active JAK inhibitor, with IC₅₀s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .

HY-14722C

NVP-BSK805 trihydrochloride	JAK	Cancer
NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-14722A

NVP-BSK805 dihydrochloride 3 Publications Verification	JAK	Cancer
NVP-BSK805 dihydrochloride is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-15999A

Cerdulatinib hydrochloride 5+ Cited Publications PRT062070 hydrochloride; PRT2070 hydrochloride	Syk JAK	Cancer
Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC₅₀s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and *Tyk2, JAK1*, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies .

HY-14722

NVP-BSK805 3 Publications Verification	JAK	Cancer
NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-168339

Tyk2-IN-22	JAK	Inflammation/Immunology
Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits *Tyk2, JAK1*, and JAK3 with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation .

HY-153440

JAK-IN-25	JAK	Cancer
JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC₅₀s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC₅₀ of 28 nM. JAK-IN-25 has the potential for cancer research ^[1].

HY-126242S

Tyk2-IN-7	JAK	Inflammation/Immunology
Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model .

HY-169984S

Tyk2-IN-22-d3	Isotope-Labeled Compounds STAT JAK	Inflammation/Immunology
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits *Tyk2, JAK1*, and JAK3 with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation .

Cat. No.	Product Name	Chemical Structure

HY-126242S

Tyk2-IN-7
Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model .

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model .

HY-169984S

Tyk2-IN-22-d3
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for tyrosine kinase 2 (Tyk2), that it inhibits *Tyk2, JAK1*, and JAK3 with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5 phosphorylation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.